| Year |
Citation |
Score |
| 2019 |
Hutchaleelaha A, Patel M, Washington C, Siu V, Allen E, Oksenberg D, Gretler DD, Mant T, Lehrer-Graiwer J. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease. British Journal of Clinical Pharmacology. PMID 30743314 DOI: 10.1111/Bcp.13896 |
0.312 |
|
| 2017 |
Metcalf B, Chuang C, Dufu K, Patel MP, Silva-Garcia A, Johnson C, Lu Q, Partridge JR, Patskovska L, Patskovsky Y, Almo SC, Jacobson MP, Hua L, Xu Q, Gwaltney SL, et al. Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin. Acs Medicinal Chemistry Letters. 8: 321-326. PMID 28337324 DOI: 10.1021/Acsmedchemlett.6B00491 |
0.34 |
|
| 2016 |
Oksenberg D, Dufu K, Patel MP, Chuang C, Li Z, Xu Q, Silva-Garcia A, Zhou C, Hutchaleelaha A, Patskovska L, Patskovsky Y, Almo SC, Sinha U, Metcalf BW, Archer DR. GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease. British Journal of Haematology. PMID 27378309 DOI: 10.1111/Bjh.14214 |
0.339 |
|
| 2016 |
Lehrer-Graiwer J, Howard J, Hemmaway CJ, Awogbade M, Telfer P, Layton M, Porter JB, Mant T, Dufu K, Hutchaleelaha A, Oksenberg D, Patel M, Tonda ME, Bridges K, Ramos E. Long-Term Dosing in Sickle Cell Disease Subjects with GBT440, a Novel HbS Polymerization Inhibitor Blood. 128: 2488-2488. DOI: 10.1182/Blood.V128.22.2488.2488 |
0.303 |
|
| 2015 |
Lehrer-Graiwer J, Howard J, Hemmaway CJ, Awogbade M, Telfer P, Layton M, Mant T, Dufu K, Hutchaleelaha A, Koller T, Oksenberg D, Patel M, Ramos E. GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease Blood. 126: 542-542. DOI: 10.1182/Blood.V126.23.542.542 |
0.302 |
|
| 2015 |
Hutchaleelaha A, Patel M, Silva A, Oksenberg D, Metcalf B. GBT440 Demonstrates High Specificity for Red Blood Cells in Nonclinical Species Blood. 126: 2172-2172. DOI: 10.1182/Blood.V126.23.2172.2172 |
0.317 |
|
| 2014 |
Patel M, Cabrales P, Dufu K, Metcalf B, Sinha U. GTx011, an Anti-Sickling Compound, Improves SS Blood Rheology By Reduction of HbS polymerization Via Allosteric Modulation of O2 Affinity Blood. 124: 1370-1370. DOI: 10.1182/Blood.V124.21.1370.1370 |
0.302 |
|
| 2012 |
Beaumont KA, Smit DJ, Liu YY, Chai E, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Sturm RA. Melanocortin-1 receptor-mediated signalling pathways activated by NDP-MSH and HBD3 ligands. Pigment Cell & Melanoma Research. 25: 370-4. PMID 22364200 DOI: 10.1111/J.1755-148X.2012.00990.X |
0.556 |
|
| 2012 |
Huang ZM, Chinen M, Chang PJ, Xie T, Zhong L, Demetriou S, Patel MP, Scherzer R, Sviderskaya EV, Bennett DC, Millhauser GL, Oh DH, Cleaver JE, Wei ML. Targeting protein-trafficking pathways alters melanoma treatment sensitivity Proceedings of the National Academy of Sciences of the United States of America. 109: 553-558. PMID 22203954 DOI: 10.1073/Pnas.1118366109 |
0.53 |
|
| 2011 |
Beaumont KA, Wong SS, Ainger SA, Liu YY, Patel MP, Millhauser GL, Smith JJ, Alewood PF, Leonard JH, Sturm RA. Melanocortin MC1 receptor in human genetics and model systems European Journal of Pharmacology. 660: 103-110. PMID 21199646 DOI: 10.1016/J.Ejphar.2010.11.040 |
0.524 |
|
| 2010 |
Patel MP, Cribb Fabersunne CS, Yang YK, Kaelin CB, Barsh GS, Millhauser GL. Loop-swapped chimeras of the agouti-related protein and the agouti signaling protein identify contacts required for melanocortin 1 receptor selectivity and antagonism. Journal of Molecular Biology. 404: 45-55. PMID 20831872 DOI: 10.1016/J.Jmb.2010.08.054 |
0.548 |
|
| 2007 |
Seballos L, Richards N, Stevens DJ, Patel M, Kapitzky L, Lokey S, Millhauser G, Zhang JZ. Competitive binding effects on surface-enhanced Raman scattering of peptide molecules. Chemical Physics Letters. 447: 335-339. PMID 20648229 DOI: 10.1016/J.Cplett.2007.09.040 |
0.536 |
|
| Show low-probability matches. |